Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$11.54B
Positions
124
New
8
Increased
22
Decreased
12
Sold Out
6
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $11.54B across 124 positions in their Q4 2017 SEC 13F filing (period ending 2017-12-31). The top 10 positions account for 81.7% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $3.24B | 28.10% | +0.0% |
| 2 | SGENEURSeattle Genetics, Inc. | $2.45B | 21.20% | - |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | $1.02B | 8.87% | - |
| 4 | ACADACADIA Pharmaceuticals Inc. | $819.85M | 7.11% | +5.5% |
| 5 | BMRNBioMarin Pharmaceutical Inc. | $676.18M | 5.86% | +28.4% |
| 6 | GHDXGenomic Health, Inc. | $471.31M | 4.09% | +0.0% |
| 7 | ONCBeiGene, Ltd. | $376.15M | 3.26% | -1.3% |
| 8 | DBV Technologies S.A. | $135.53M | 1.17% | - |
| 9 | Aquinox Pharmaceuticals, Inc. | $128.59M | 1.11% | - |
| 10 | ASNDUSDAscendis Pharma A/S | $104.91M | 0.91% | +11.5% |
| Stock | Value | Shares |
|---|---|---|
| Ablynx NV | $103.99M | 4,161,118 |
| ERYP1EURErytech Pharma S.A. | $68.04M | 3,090,069 |
| RYTMRhythm Pharmaceuticals, Inc. | $59.55M | 2,049,020 |
| NKTREURNektar Therapeutics | $10.27M | 171,934 |
| QUREuniQure N.V. | $9.45M | 482,557 |
| CRBPEURCorbus Pharmaceuticals Holdings, Inc. | $4.69M | 660,714 |
| Endocyte, Inc. | $4.65M | 1,087,323 |
| IFRXInflaRx N.V. | $4.19M | 200,000 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.